AEE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Ameren Corp (AEE) is not a strong buy at the moment for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. While the company has positive financial growth trends and an optimistic outlook from analysts, the technical indicators and insider selling trends suggest a lack of immediate upward momentum. Additionally, no strong trading signals or significant catalysts are present to justify an immediate purchase.
The stock's MACD is negative and expanding, indicating bearish momentum. RSI is neutral at 49.977, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key support is at 109.593, and resistance is at 113.291. The stock is trading near its pivot point of 111.442, showing no clear breakout signal.
Analysts have raised price targets recently, with UBS setting a target of $127 and Mizuho at $117, both maintaining positive ratings.
Strong financial performance in Q4 2025, with net income up 21.74% YoY and EPS up 19.48% YoY.
Ameren's issuance of $400 million in senior notes at favorable rates to improve its financial structure.
Insiders are selling, with a 134.38% increase in selling activity over the last month.
The broader utilities sector has underperformed the S&P 500 recently, as noted by analysts.
The stock's price has declined in the regular market (-1.69%) and pre-market (-0.61%), indicating weak short-term momentum.
In Q4 2025, Ameren reported a revenue decline of -8.19% YoY to $1.782 billion. However, net income increased by 21.74% YoY to $252 million, EPS grew by 19.48% YoY to 0.92, and gross margin improved significantly by 32.44% YoY to 57.52%. This indicates strong profitability despite a revenue drop.
Analysts are generally optimistic about Ameren, with multiple firms raising price targets. UBS has the highest target at $127 with a Buy rating, while Morgan Stanley and others maintain more conservative targets around $116-$120 with Equal Weight or Outperform ratings. Analysts highlight Ameren's capital plan revisions and potential for EPS growth above long-term targets as key positives.
